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Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome
(SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at
baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week
washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Proﬁle (SIP), Short
Form 36 (SF 36), and Inﬂammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant
adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suﬀering from Crohns disease, it progressed
to abdominal pain and led to discontinuation of GLP-2 treatment. One had a ﬁbrostenotic lesion electively resected at the jejuno-
ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all
9 jejunostomy patients. Reported GLP-2 compliance was excellent (>93%). GLP-2 improved the overall quality of life VAS-score
(4.1±2.8cmversus6.0±2.4cm,P<. 01), the overall SIP score (10.3±8.9% versus 6.2±9.5%, P<. 001), the mental component
of the SF-36 (45 ± 13% versus 53 ± 11%, P<. 05), and the overall IBDQ score (5.1 ± 0.9v e r s u s5 .4 ± 0.9, P<. 007) in the 8
patients completing the study. Conclusions. Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be
exercised in patients with a history of abdominal pain. Although conclusions cannot be made in a noncontrolled trial, the high
reportedcompliancemightreﬂectahightreatmentsatisfaction,wheretheclinicalbeneﬁtsofGLP-2mayoutweighthediscomforts
of injections.
Copyright © 2009 P. B. Jeppesen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Until recently, the medical treatment options in short bowel
patients with intestinal insuﬃciency or failure were based on
antidiarrhoeals (codeine, opium, and loperamide) and anti-
secretory agents (H2-receptor blockers and proton pump
inhibitors). Now, growth factors such as growth hormone
and glucagons-like peptide 2 have been suggested as treat-
ment options in these patients. In fact, the FDA approved
growth hormone (Zorbtive) for the treatment of short bowel
syndrome (SBS) patients with intestinal failure in 2003.
The eﬀects of growth hormone on intestinal function are
controversial, and serious side eﬀects, due to the systemic
eﬀects of growth homone, such as myalgia, arthralgia,
gynecomastia, carpal tunnel syndrome, nightmares, and
insomnia,arereportedevenintherelativeshort-termstudies
[1]. These side eﬀects may limit the acceptance of long-term
administration and may impair the quality of life of the
HPN patients. The more targeted eﬀects of Glucagon-like
peptide 2 (GLP-2) and a dipeptidyl-peptidase IV (DPP-IV)
degradation-resistantgly-2GLP-2analogue[2],Teduglutide,2 Gastroenterology Research and Practice
on intestinal function, and the relative few side eﬀects
describedinshort-termstudies,seeminglymaketheseagents
more attractive [3, 4]. However, since they have only been
used for maximum 35 days, the current study seeks to
evaluate the feasibility and acceptance of long-term GLP-2
treatment in patients with intestinal insuﬃciency or failure.
In this respect, compliance and safety issues were addressed
in eleven patients, who were oﬀered GLP-2 for subcutaneous
injection TID for two consecutive years intermitted by an 8-
week washout period. The concomitant physiological eﬀects
derived from this open-label, long-term GLP-2 study are
presented separately. The current study also describes the
longitudinal changes in quality of life evaluated by the
Sickness Impact Proﬁle (SIP) [5], the Short Form 36 (SF
36) [6], and the Inﬂammatory Bowel Disease Questionnaire
(IBDQ) [7], and treatment satisfaction was measured.
2.MaterialandMethods
2.1. Patients. Eleven SBS patients (3 female, 8 male; 47 ± 11
years; remnant small bowel 157 ± 6 6 c m ;2w i t hac o l o n ;
7 had intestinal failure, 3 receiving parenteral ﬂuids and
electrolytes exclusively and 4 receiving parenteral nutrition;
4 had intestinal insuﬃciency and did not need parenteral
nutrition or ﬂuid) were recruited to the study based on a
fecal energy excretion exceeding 2.0MJ/day (measured at a
previous admission) or a remnant small bowel of 200cm or
less(measuredpreoperativefromtheligamentofTreitz).The
short bowel syndrome was a consequence of inﬂammatory
bowel disease in all patients. The patients did not have
activity in their IBD as evaluated clinically, and none of the
patients received maintenance medication. The individual
patient characteristics at baseline are presented in Table 1.
2.2. Study Protocol. Over the two years, the patients were
admitted at least eight times to the hospital for 72-hour
evaluations. After the baseline evaluations, the patients
were given native GLP-2, 400mcg TID, subcutaneous, for
one year. For these studies we employed synthetic human
GLP-2, corresponding to human proglucagon 126–158,
custom-synthesized by PolyPeptide Laboratories GmbH,
Wolfenb¨ uttel, Germany, as described previously [3]. The
patients were scheduled for readmissions at 13, 26, and 52
weeks (abbreviated Y1-W13, Y1-W26, Y1-W52, resp.). After
the ﬁrst readmission at week 13, the patients were given an
option to test a double dose of GLP-2, 800mcg TID for 3
weeks. The patients, who accepted, were readmitted for an
extra 72-hour nutrient balance study at week 17 (Y1-W17).
Aftercompletingthisevaluation,theoriginalGLP-2dosewas
reintroduced. GLP-2 treatment was discontinued for 8 weeks
after the ﬁrst 52 weeks of treatment. After a 72-hour follow-
up evaluation, the GLP-2 treatment, 400mcg TID, was re-
introduced and evaluations were repeated during admission
at 13, 26, and 52 weeks during the second year of treatment
(abbreviated Y2-W13, Y2-W26, Y2-W52, resp.). In relation
to the week 26 readmission, during the second year of
GLP-2 treatment, the patients were given cholylsarcosine
bile acid replacement therapy, 2g TID, two days prior to
the admission and during the 72-hour balance studies.
Cholylsarcosinewasintroducedsinceithasbeendescribedto
increase fat absorption in SBS patients. Cholylsarcosine was
packed into gelatine capsules (250mg/capsule) as described
previously [8]. Cholylsarcosine was taken in relation to the
three main meals and in conjunction with subcutaneous
GLP-2 injections.
2.2.1. Compliance and Safety. The patients were asked to
ﬁll in deviations from their daily medical and parenteral
prescriptions in a patient diary, and GLP-2 compliance was
evaluated and crosschecked by counting returned empty
vials. The patients also described eﬀects and side eﬀects
of GLP-2 treatment in this diary. During the 72-hour
admissions, the patients were monitored for safety (adverse
events, physical exams, injection site examinations, and
standard laboratory results).
2.2.2. Quality of Life and Treatment Satisfaction. During
admissions, the patients were instructed to ﬁll in three val-
idated questionnaires regarding quality of life: The Sickness
Impact Proﬁle (SIP) [5], the Short Form 36 (SF 36) [6],
and the Inﬂammatory Bowel Disease Questionnaire (IBDQ)
[7]. The SIP and SF 36 questionnaires are designed to
be broadly applicable across types and severities of illness
and across demographic and cultural subgroups. They were
chosen for this study to provide a measure on the non-
disease-speciﬁc function of the patients. The IBDQ was
developed to measure subjective health status for patients
with inﬂammatory bowel disease. This questionnaire is
disease-speciﬁc and was chosen to focus on bowel-related
symptoms and the impact on quality of life.
The SIP measures sickness-related dysfunction and is
designed to cover patient perception of performance in areas
of activity in everyday life. It contains 136 items in two
main dimensions and 5 independent categories in areas
of activity; Physical (ambulation and mobility, body care
and movement), psychosocial (social interaction, alertness
and emotional behavior, communication), and independent
categories (sleep and rest, eating, work, home keeping,
recreation, and pastimes). Patients were asked to endorse or
check those statements that were in accordance with their
present situation. No positive answers were equivalent to
no behavioral dysfunction. The SIP percent scores of the
dimensions and categories were obtained by summing the
numberofpositivestatementstotheitemsineachdimension
and category, dividing that sum by the total sum of the
possible values and multiplying the quotient by 100. Zero
percent indicates the best possible function (absence of
dysfunction),whereas100%indicatespresenceofallpossible
dysfunctional behavior. At the end of the SIP questionnaire
patients were asked to mark their overall quality of life on
a 9cm visual analogue scale (VAS). At the left at 0cm a
miserable quality of life was indicated, whereas an ideal
quality of life was indicated at 9cm at the right end of the
scale.
The SF 36 measures eight multi-item variables: physical
functioning (10 items), role limitations due to physicalGastroenterology Research and Practice 3
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problems (four items), pain (two items), general perception
of health (ﬁve items), social functioning (two items), role
limitations due to emotional problems (three items), mental
health (ﬁve items), and energy and vitality (four items).
For each variable items, scores are coded summed, and
transformed on to a scale from 0 (worst possible health state
measured by the questionnaire) to 100 (best possible health
state). The physical component summary includes the four
ﬁrst items and the mental component summary includes the
last four items.
The 32-item IBDQ questionnaire examines four aspects
of patients’ lives: symptoms directly related to the primary
bowel disturbance (10 questions), systemic symptoms (5
questions), emotional (12 questions), and social function
(5 questions). The response options for each question were
framed as a seven-point scale at which 7 represented best
function and 1 represented worst function. The scores of
each aspect have been given as mean on the 7-point scale.
In addition to the three validated questionnaires regard-
ing quality of life, an evaluation-form containing questions
regarding treatment satisfaction in relation to GLP-2 treat-
ment was given to the patients after the two years of GLP-
2 treatment. At week 26 during the second year of GLP-
2 treatment, where the patients also received oral bile acid
replacement therapy, the patients were questioned weather
they preferred subcutaneous GLP-2 (400µgT I D )o ro r a l
capsules with cholylsarcosine (2g∼8 capsules TID) on the
assumption, that the eﬀect was the same.
3. Ethics
The Ethics Committee for Medical Research in Copenhagen,
Denmark, (KF 01-235/98) approved the protocol. Proce-
dures followed were in accordance with the ethical standards
of the Helsinki Declaration of 1975, as revised in 1983.
Patients signed informed consent before entrance to the
study.
4. Statistics
The diﬀerences between admissions periods were tested
with a Friedman repeated measures analysis of variance
on ranks on using the SigmaStat for Windows Version
2.0 (Copyright 1992–1995, Jandel Corporation, Erkrath,
Germany)in patients completing the study. For comparisons
of admission periods to the baseline period, the Dunnett
method was used as the post hoc test. The frequencies
of conﬁrmatory answers in the SIP questionnaire were
compared by the chi-square, alternatively Fisher exact test.
Av a l u eo fP<. 05 was considered signiﬁcant.
5. Results
5.1. Compliance and Safety. The compliance reﬂects the
tradeoﬀ between the clinical beneﬁts of receiving GLP-2
or possible secondary beneﬁts perceived by the patient in
relation to participating in the study versus the side eﬀects,
discomforts (from injections, frequent admissions, study-
related invasive procedures, etc.), and potential risks in
relation to treatment. In this respect 3 of the 11 patients did
not complete the study.
Patient O. B. chose to discontinue GLP-2 after 232 days
of treatment due to aggravation of chronic, intermittent,
abdominal pain and nausea. A barium follow-through did
not reveal a small bowel obstruction, and the patient
had no clinical or biochemical evidence of activity in his
Crohn’s disease. The condition improved in relation to
discontinuation of treatment. The patient had a compliance
of 93% of injections prior to discontinuing GLP-2 treatment.
Patient J. P. discontinued GLP-2 treatment at day 160
during the second year of the study due to signs of
bowel obstruction. A barium follow-through revealed a
short-segment relative obstruction at the jejuno-ascendo-
anastomosis. An elective resection of a ﬁbrostenotic lesion
of less than 5cm at the anastomosis was performed. There
were no macroscopic or microscopic signs of active Crohn’s
disease. Compliance was 100% the ﬁrst year and 94% until
treatment was discontinued the second year. The patient did
not want to continue GLP-2 treatment after the resection.
Patient E. F. P. was excluded from the study by the
investigator after 174 days of GLP-2 treatment during the
second year of the study. The patient could not account for
the dispensed GLP-2 vials and admitted to disposing them
instead of returning them. At this point, it became evident
that she had stopped ﬁlling in the patient diary, and that
her reliability could be questioned due to an escalating abuse
of analgesics. As evaluated by the returned vials and the
diary, the compliance was 100% the ﬁrst year of treatment.
According to the patient, she had taken “most injections”
during the second year of treatment until exclusion. She
discontented with the decision to exclude her, since she had
experienced positive eﬀects of GLP-2.
Intheremainingeightpatients,whocompletedthestudy,
the compliance was more than 94% during both years of
GLP-2 treatment.
5.2. Adverse Events. Two study-related serious adverse events
occurred.PatientG.L.experiencedadistalbowelperforation
followingstudy-relatedbiopsiestakenthroughtheileostomy,
prior to the initiation of GLP-2 treatment. A new ileostomy
was created after resection of 5cm of small bowel. After
time for recovery from surgery, the patient insisted on
inclusion in the study, but he refused the biopsy scheduled
for week 52. Patient J. H. J. experienced prolonged venous
bleeding from the stoma after having biopsies taken at week
52. In contrary to instructions, the patient had taken a
GLP-2 injection just prior to having the biopsies taken.
The bleeding stopped spontaneously, but the patient was
given two transfusions due to a drop in hemoglobin from
7.2mmol/L to 5.3mmol/L.
Other adverse events included a transient tender
abdomen in relation to the initiation of GLP-2 treatment
described in 5 of 11 patients (Patients H. R. M., O. B., J. P.,
E. F. P., J. E., and U. D. J.). Reduced appetite and peripheral
edema was described in 2 of 11 patients (Patients H. R. M.Gastroenterology Research and Practice 5
andE.F.P.).Sixoutof11patientreported,thattheyurinated
morethanhabituallyinrelationtoGLP-2treatment(Patients
H. R. M., L. M., J. P., E. F. P., J. E., and J. H. J.). Nine of
11 patients described a reduction in their fecal excretions
leading to a reduction in their frequency of defecation or
emptying of their stoma bags (all, except patients O. B., and
F. V. L.). Over the two years of treatment 5 of the 7 HPN
p a t i e n t s( P a t i e n t sH .R .M . ,J .P . ,E .F .P . ,J .H .J . ,a n dU .D .
J.) experienced 16 episodes of catheter-related bacteremia.
Seven of these episodes were seen in the patient E. F. P., who
had an escalating abuse of analgesics, and who was excluded
from the study due to the failure to document compliance.
5.3. Physical Exams. The most consistent ﬁnding during
physical exams in relation to GLP-2 treatment was enlarge-
ment of the stoma nipple seen in all the 9 patients with
a stoma. In general, the patients detected the enlargement
within a week after initiation of GLP-2 treatment, and it
persisted throughout the treatment periods. The enlarge-
ment reversed toward normal size within a week after
discontinuation of GLP-2 treatment.
5.4. Injection Site Examinations. There were no generalized
skin reactions in relation to GLP-2 treatment, and in only
two cases, local injection site reactions appearing as small
hematomas were seen at admissions in relation to the GLP-2
injections (Patients H. R. M., and J. H. J.).
5.5. Standard Laboratory Results. No signiﬁcant changes
were seen regarding the following standard laboratory
results in relation to GLP-2 treatment: hemoglobin, ery-
throcyte volume fraction, thrombocytes, leucocytes, sed-
imentation, albumin, protein, C-reactive protein, alanin-
aminotransferases,alkaline phosphatases,amylase,bilirubin,
urea, sodium, potassium, total or ionized calcium, and
magnesium. Plasma creatinine decreased at all timepoints in
relation to GLP-2 treatment (range 0.086 ± 0.024mmol/L,
Y2-W52, to 0.101 ± 0.029mmol/L, Y2-W26) compared to
baseline values (0.103 ± 0.019mmol/L,P<. 05). Plasma-
CO2-total increased from 21.9 ± 3.0mmol/L at baseline
(normal range 25.0 − 32.0mmol/L) to mean values ranging
from 23.4 ± 2.4mmol/L (Y1-W13) to 27.3 ± 4.0mmol/L
(Y2-W52) in relation to GLP-2 treatment (P<. 001).
Plasma phosphate increased from a baseline value of 0.93 ±
0.16mmol/L (normal range 0.80 − 1.50mmol/L) to 1.18 ±
0.23mmol/L (Y1-W13, P<. 05) and to 1.12 ± 0.26mmol/L
(Y1-W26, P<. 05) during the ﬁrst year of GLP-2 treat-
ment, and increases were also seen the second year (Y2-
W26: 1.13 ± 0.15mmol/L,P<. 05 and Y2-W52: 1.06 ±
0.211.06±0.21mmol/L,P<. 05).Thephysiologicalbasisand
implications of these ﬁndings are discussed separately.
5.6. Quality of Life and Treatment Satisfaction. The eﬀect of
GLP-2 on quality of life evaluated by SIP is presented in
Table 2. The overall SIP scores were signiﬁcantly better at
treatment weeks 26 and 52 during both years of treatments
compared to baseline. Neither the physical or psychosocial
dimensions or the independent categories gave statistically
clear pictures of what caused this positive result, but in
generalnumericalimprovementswereseenwithinalldimen-
sions and categories at treatment weeks 26 and 52 during
both years of treatments compared to baseline (Table 2).
The VAS scores improved signiﬁcantly at all admissions in
relation to GLP-2 treatment from a baseline value of 4.1 ±
2.8cm to values ranging from 5.1 ± 2.8cm (Y1-W13) to
6.0 ±2.4cm (Y2-W52).
The eﬀect of GLP-2 on quality of life evaluated by SF-
36 is presented in Table 3. No changes were seen regarding
physical function, limitation based on physical function,
physical pain or general well-being, whereby no signiﬁcant
changes were seen in the physical component summary.
No changes were seen regarding energy, social function, or
limitations based on mental function in relation to GLP-2
treatment. Mental function and well-being was signiﬁcantly
better at weeks 13 and 52 of the ﬁrst year and during
weeks 13, 26, and 52 of the second year of GLP-2 treatment
compared to baseline (P<. 05). The mental component
summary was signiﬁcantly improved at week 52 of the ﬁrst
year of GLP-2 treatment compared to baseline (P<. 05).
Numerically, the overall IBDQ scores were signiﬁcantly
better at all treatment points during the two years of GLP-
2t r e a t m e n t( P = .007), but the post hoc pair-wise test
of diﬀerences between admission periods and the baseline
periodwerenegative(Table 4).Theoverallpositive eﬀectson
IBDQ scores seemed to be mediated through positive eﬀects
ofGLP-2onsystemicsymptomsandsocialfunction,whereas
bowel symptoms and emotional function was unaﬀected by
GLP-2 treatment.
The results of the treatment satisfaction questionnaire
are given in Table 5. Overall, the satisfaction with GLP-
2 treatment was high, and all patients would recommend
GLP-2 patients to others, who shared their symptoms.
All eight patients receiving Cholylsarcosine responded that
they preferred taking GLP-2 injections TID compared to
consuming Cholylsarcosine capsules (2g/day, eight capsules)
TID on the assumption, that the eﬀect was the same.
6. Discussion
Patients with intestinal failure frequently require life-long
parenteral nutrition. Although providing good nutritional
recovery, the complex technology of home parenteral nutri-
tion may reduce the quality of life [9], and cause serious
complications, such as sepsis, venous thrombosis, metabolic
bone disease, renal impairment, and liver disease [10–13].
Small bowel transplantation is an exciting alternative, but it
isstillmainlyconsideredforpatientsfailingonHPN[11,14].
It has been speculated that GLP-2 could enhance small
bowel adaptation and absorption, thereby possibly increas-
ing the quality of life by reducing fecal excretions, the need
for parenteral nutrition, and the incidence of HPN-related
complications. Preliminary results from “proof of concept,”
short-term studies have demonstrated clinically meaningful
increases in intestinal absorption in relation to 35 days of
treatment with native GLP-2 [3] and 21 days of treatment
with the analog teduglutide [4]. However, the eﬀects of these6 Gastroenterology Research and Practice
Table 2: Sickness impact proﬁle, SIP (0% ∼Best).
(mean±SD,n = 8) 1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2
GLP-2 +
Cholyl-
sarcosine
GLP-2 —
Overall 10.3 ±8.99 .7 ±10.27 .6 ±11.4 § 6.2 ±9.5 §§§ 7.8 ±8.38 .6 ±9.6 7.2 ±10.5 § 6.7 ± 8.4 §§ —
Body care and
movement
2.8 ±4.11 .0 ±1.92 .1 ±3.31 .5 ±2.12 .8 ±4.12 .6 ±4.6 4.3 ±5.7 2.1 ±3.3—
Mobility 13.8 ±18.51 3 .8 ±20.77 .5 ±17.57 .5 ±13.97 .5 ±10.41 1 .3 ±18.9 12.5 ±25.5 8.8 ± 18.1—
Ambulation 5.3 ±7.86 .3 ±9.81 .0 ±2.82 .1 ±6.05 .3 ±7.84 .3 ±7.9 3.1 ±6.3 4.1 ±8.9—
Physical
Dimension
5.9 ±7.85 .4 ±7.63 .0 ±6.13 .0 ±5.54 .3 ±5.15 .0 ±7.6 5.8 ±9.6 4.3 ±7.3—
Emotional
behaviour
9.7 ±9.38 .3 ±11.56 .9 ±15.64 .2 ±8.32 .8 ±5.18 .3 ±11.5 5.6 ±11.9 6.9 ± 13.2—
Social interaction 16.3 ±18.71 8 .1 ±21.51 1 .9 ±18.58 .8 ±18.91 0 .0 ±13.61 0 .0 ±14.8 7.5 ±12.2 § 9.4 ± 10.2—
Alertness
behaviour
16.2 ±29.22 2 .5 ±27.11 6 .3 ±21.31 3 .8 ±20.01 7 .5 ±24.32 7 .5 ±38.5 10.0 ±16.0 16.3 ±27.7—
Communication 0.0 ±0.00 .0 ±0.01 .4 ±3.91 .4 ±3.90 .0 ±0.00 .0 ±0.0 0.0 ±0.0 0.0 ±0.0—
Psychosocial
Dimension
11.9 ±11.61 3 .9 ±15.89 .8 ±15.17 .5 ±13.78 .3 ±11.01 1 .5 ±11.1 6.1 ±9.5 §§ 8.6 ± 11.2—
Sleep and rest 21.4 ±20.21 4 .3 ±13.22 3 .2 ±32.31 6 .1 ±19.42 3 .2 ±24.11 0 .7 ±14.8 21.4 ±35.0 12.5 ±16.1—
Home
management
11.3 ±13.61 1 .3 ±16.46 .3 ±14.16 .3 ±10.68 .8 ±11.37 .5 ±11.9 8.8 ±17.3 5.0 ± 10.7—
Work 6.9 ±13.20 .0 ±0.05 .6 ±15.70 .0 ±0.02 .8 ±7.86 .9 ±13.2 2.8 ±5.1 2.8 ±7.8—
Recreation and
pastimes
25.1 ±29.22 5 .2 ±24.21 5 .8 ±27.41 7 .4 ±26.71 8 .9 ±26.82 0 .5 ±30.6 12.6 ±25.9 15.8 ±27.4—
Eating 1.6 ±4.40 .0 ±0.00 .0 ±0.01 .6 ±4.43 .1 ±5.80 .0 ±0.0 3.1 ±5.8 1.6 ±4.4—
Independent
Categories
12.8 ±10.21 0 .4 ±8.79 .3 ±12.98 .4 ±9.91 0 .8 ±10.58 .3 ±8.6 9.8 ±14.4 7.3 ± 8.9 § —
QOL VAS-score,
0–9cm,9cm∼best
4.1 ±2.85 .1 ±2.8∗ 5.8 ±2.6∗ 5.9 ±2.4∗ 4.7 ± 3.3∗ 5.8 ±2.8∗ 5.6 ±2.5∗ 6.0 ±2.4∗ 0.01
QOL VAS-score ∼ Quality of life Visual Analog Scale, ∗ ∼ P<. 05, compared to baseline by Dunnett’s test, §∼P<. 05,§§ ∼ P<. 01,§§§ ∼ P<. 001,
compared to baseline by chi-square, alternatively Fisher exact test.
treatments subsided when discontinued, and therefore long-
term, possibly life-long treatment is required. In contrast to
the previous short-term studies, where active eﬀorts were
made to enforce strict compliance to injections and adhesion
to ﬁxed diets in hospital-like settings, this study aimed at
describing the consequences of introducing and expanding
long-term GLP-2 treatment to the daily life of the short
bowel patients. The open-label, uncontrolled study-design
could be criticized, but since tolerability and safety were our
mainconcern,andsinceGLP-2treatmenthasneverexceeded
35 days in humans, this setup was believed to provide
valuable information prior to designing and conducting
larger blinded, randomized, placebo-controlled studies.
The physiological eﬀects of long-term GLP-2 treatment
inthepatientsincludedinthisstudyarepresentedseparately.
However, in summary, the GLP-2 treatment reduced fecal
wet weight losses with around 1000 mL/day, whereby the
patients needed to drink less, since the parenteral support
was kept constant. The eﬀects on energy and macronutrient
absorptionwereminor.Thisenabledthepatientstomaintain
their intestinal ﬂuid and electrolyte absorption at lower oral
intakes. A reduction in the amplitude of the daily ﬂuctua-
tions in the ﬂuid-balance in relation to GLP-2 treatment may
explain the beneﬁcial eﬀects on renal function.
G L P - 2t r e a t m e n tw a ss a f ea n dw e l lt o l e r a t e da sd e m o n -
strated by the high compliance in the SBS patients complet-
ing this study (≥94%) and also in the patients discontinuing
GLP-2 treatment (≥93%).
Considering the safety, one of the patients with Crohn’s
disease required elective surgery due to the evolvement of
a ﬁbrostenotic lesion at the neoterminal anastomosis. It is
uncertain, whether it was induced by the GLP-2 treatment
or simply reﬂected the natural history of the Crohn’s disease
in this patient. Nevertheless, it seems that caution should
be taken, when prescribing GLP-2 or analogs to patients
with a relative intestinal stenosis, a narrow stoma, or a
history of abdominal pain. GLP-2 treatment could cause a
manifest condition of bowel obstruction. In the patient O.
B., aggravation of chronic abdominal pain lead to discontin-
uation of GLP-2 treatment. In this respect, the reversibilityGastroenterology Research and Practice 7
Table 3: Short form 36, SF-36 (100% ∼Best).
(mean±SD,n = 8) 1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2 GLP-2 + Cholyl-sarcosine GLP-2
Physical Function 73 ±23 76 ±24 78 ±24 77 ±27 75 ±24 79 ±22 77 ±25 78 ±21 0.51
Limitation based
on Physical
Function
44 ±42 72 ±36 69 ±40 72 ±36 44 ±42 66 ±40 69 ±44 63 ±46 0.34
Physical Pain 82 ±20 76 ±32 81 ±31 80 ±25 80 ±23 77 ±32 79 ±26 73 ±37 0.19
General Well-being 51 ±23 46 ±20 48 ±21 48 ±20 47 ±29 47 ±22 49 ±21 47 ±20 0.84
Physical
Component
Summary
43 ±11 43 ±94 5 ±12 43 ±94 1 ±10 44 ±84 3 ±94 4 ±10 0.83
Energy 39 ±31 58 ±28 51 ±39 55 ±33 35 ±31 47 ±29 44 ±31 51 ±35 0.10
Social Function 83 ±22 88 ±27 86 ±23 88 ±22 80 ±25 84 ±26 81 ±21 75 ±35 0.44
Limitation based
on Mental
Function
71 ±45 67 ±40 67 ±36 83 ±36 63 ±42 71 ±42 79 ±40 67 ±36 0.28
Mental Function 70 ±20 83 ±18∗ 72 ±26 80 ±21∗ 70 ±20 73 ±23∗ 75 ±22∗ 76 ±20∗ 0.02
Mental Component
Summary
45 ±13 49 ±11 48 ±13 53 ±11∗ 46 ±12 50 ±11 51 ±10 46 ±14 0.02
∗
∼ P<. 05, Compared to Baseline by Dunnett’s alternatively Bonferoni’s test.
Table 4: Inﬂammatory Bowel Disease Questionnaire, IBDQ (7∼Best).
(mean ±SD,n = 8) 1st year 2nd year
Baseline Week 13 Week 26 Week 52 Washout Week 13 Week 26 Week 52 P-value
Treatment None GLP-2 GLP-2 GLP-2 None GLP-2 GLP-2 + Cholyl-sarcosine GLP-2
Overall 5.1 ±0.95 .3 ±0.95 .3 ±1.05 .4 ±0.94 .9 ±1.05 .4 ±0.85 .5 ±0.85 .4 ± 0.9 0.007
Bowel Symptoms 5.3 ±0.65 .5 ±0.85 .3 ±0.85 .5 ±0.75 .2 ±0.85 .5 ±0.65 .5 ±0.85 .4 ± 0.70 . 6 1
Systemic Symptoms 4.0 ±1.44 .5 ±1.64 .9 ±1.44 .7 ±1.23 .7 ±1.64 .2 ±1.44 .4 ±1.34 .9 ± 1.40 . 0 3
Emotional Function 5.5 ±1.15 .7 ±1.15 .6 ±1.25 .7 ±1.15 .5 ±1.15 .7 ±0.85 .9 ±0.85 .7 ± 1.00 . 4 4
Social Function 5.0 ±1.35 .0 ±1.55 .2 ±1.45 .1 ±1.44 .5 ±1.45 .3 ±1.55 .4 ±1.15 .3 ± 1.40 . 0 3
∗
∼ P<. 05, compared to baseline by Dunnett’s test.
of the treatment eﬀect and the short half-life of GLP-2
are appreciated. However, all patients should be informed,
that mild, but normally transient, abdominal tenderness is
likely to occur when introducing GLP-2 treatment. Patients
with an ostomy should also be advised to enlarge the access
connection to their ostomy bags, since the stoma nipple will
enlarge in relation to GLP-2 treatment. The cause of this
enlargement is unknown, but it could relate to increased
intestinal blood ﬂow and blood congestion in the stoma
nipple [15], whereas structural and morphological changes
in the gut mucosa, as described separately, are minor.
The occurrence of two serious adverse events in relation
to study-related biopsy procedures highlights that caution
should be taken when obtaining biopsies from the small
bowel through ostomies and questions their necessity in the
presence of better non-invasive clinical endpoints.
The general reports in the safety diaries of reductions
in fecal output and increases in the need to urinate simply
reﬂect the positive eﬀects of GLP-2 on intestinal ﬂuid
absorption. These positive eﬀects may, if the parenteral ﬂuid
support or the oral intake is not reduced accordingly, lead to
peripheral edema (as evidenced in patients H. R. M., and E.
F. P.) and theoretically to cardiac insuﬃciency and failure in
susceptible patients.
A high incidence of catheter-related bacteremia was
recorded during GLP-2 treatment (16 episodes during two
yearsinthe7patientsreceivingH.P.N.).However,excluding
the seven episodes in patient E. F. P., who could no longer
manage either study medication or HPN independently, the
incidence approached what is described in the Danish HPN
cohort [16].
Surveillance of standard laboratory tests obtained during
the two years of GLP-2 treatment did not raise concerns.
As described separately, the reduction in plasma creatinine
and the increase in plasma-CO2-total in relation to GLP-2
treatment probably reﬂect the beneﬁcial eﬀects of GLP-2 on
renal function mediated trough a reduction in the amplitude
of the daily ﬂuctuations in the ﬂuid-balance in relation to
GLP-2 treatment.8 Gastroenterology Research and Practice
Table 5: Evaluation of treatment satisfaction.
1∼Totally Agree, 2∼Agree a lot, 3∼Agree, 4∼Disagree, 5∼Disagree a lot, 6∼Totally disagree (n = 8,mean ±SD)
1. GLP-2 allows me to do, what I please to do. 2.8 ±1.7
2. I would deﬁnitely recommend the GLP-2 medication to others who share my symptoms. 1.1 ±0.4
3. I am not satisﬁed with the medication I current receive for my symptoms. 5.1 ±1.2
4. I am satisﬁed with the rapid onset of action of GLP-2. 1.9 ±1.0
5. I feel, that GLP-2 is the best medication available on the market for me. 2.1 ±1.8
6. I am satisﬁed with the GLP-2 medication that I have received for my symptoms. 1.5 ±0.8
7. The medication enables med to eat and drink whatever I please. 2.4 ±1.7
To describe changes in quality in life in relation to
GLP-2 treatment, we used the validated global, SIP and
SF-36 questionnaires, and a more disease-speciﬁc, IBDQ,
questionnaire. However, not even the IBDQ questionnaire
is designed to focus on speciﬁc disabilities in relation to
living with a stoma and the need for parenteral support.
Furthermore, a uniform response to GLP-2 treatment is
unlikely to occur. In some patients, the physiological ben-
eﬁts of GLP-2 on intestinal function may improve their
social life, whereas others may focus on the eﬀects on
physical function. In general, GLP-2 improved the overall
SIP scores and VAS-scores, and numerical, but nonsignif-
icant, improvements were also detected regarding the SF-
36 and IBDQ scores. It seems that the eﬀects of GLP-
2 are most pronounced in the psychosocial and mental
domains, whereas the eﬀects on bowel symptoms and
general physical functions are less pronounced. The high
compliance and treatment satisfaction (Table 5) suggests
that the physiological eﬀects and the magnitudes of these
changes in measures of quality of life in relation to GLP-
2 treatment are clinically relevant. Currently, the annual
cost of GLP-2 treatment in the doses given in this study
approximates 50.000 $. Although more time consuming,
qualitative interviews may be more suitable in exploring the
more detailed eﬀects of GLP-2 in the individual patients, and
validated questionnaires focusing on issues more relevant for
the quality of life in HPN patients are currently developed
and tested.
The patients preferred to take GLP-2 injections TID
compared to consuming Cholylsarcosine capsules TID.
According to all patients, long-term acceptance of 8 capsules
TID would be diﬃcult, and the clinical applicability of long-
term oral Cholylsarcosine treatment in the present form and
dose therefore seems limited.
In conclusion, the main eﬀect of GLP-2 treatment in
patients with short bowel syndrome is a reduction in fecal
losses of ﬂuid and electrolytes, whereas eﬀects on energy
and macronutrient absorption are minor. This enables the
patients to maintain their intestinal ﬂuid and electrolyte
absorption at lower oral intakes. Although side-eﬀects,
that is, abdominal pain and intestinal stenosis, lead to
discontinuation of treatment in two patients in this study,
the high compliance, treatment satisfaction, and positive
trends in measures of quality of life over two years indicate
that the reduction in fecal wet weight excretion of around
1000g per day and a reduction in the need to compensate by
hyperphagia/hyperdipsia in the same magnitude is desirable
from a patients perspective and outdo the discomforts of
injections. An alternative strategy for the HPN patients
is maintaining hyperphagia/hyperdipsia in order to reduce
their need for parenteral support. In this respect, the
patients near both sides of the limit between intestinal
insuﬃciency and intestinal failure are likely to achieve the
largest improvements in quality of life, since treatment will
eithergetthemoﬀorkeepthemoﬀparenteralsupport.Based
on evaluations of the HPN volumes needed in the Danish
HPN-cohort, theoretically approximately 10–15% of short
bowel patients with intestinal failure may be able to regain
intestinal autonomy, may be weaned from H. P. N., and may
have their central line removed in relation to treatment with
GLP-2, 400ug TID, provided that they are able to maintain
their hyperphagia. According to most patients in this study,
the beneﬁts of GLP-2 are welcome in the limited treatments
armamentarium of the short bowel syndrome.
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